Literature DB >> 11857353

Lysosomal proteases as potential targets for the induction of apoptotic cell death in human neuroblastomas.

Roberta Castino1, Deborah Pace, Marina Démoz, Marco Gargiulo, Chiara Ariatta, Elisabetta Raiteri, Ciro Isidoro.   

Abstract

Neuroblastoma is the most common type of cancer in infants. In children this tumor is particularly aggressive; despite various new therapeutic approaches, it is associated with poor prognosis. Given the importance of endosomal-lysosomal proteolysis in cellular metabolism, we hypothesized that inhibition of lysosomal protease would impact negatively on neuroblastoma cell survival. Treatment with E-64 or CA074Me (2 specific inhibitors of cathepsin B) or with pepstatin A (a specific inhibitor of cathepsin D) was cytotoxic for 2 neuroblastoma cell lines having different degrees of malignancy. Cell death was associated with condensation and fragmentation of chromatin and externalization of plasma membrane phosphatidylserine, 2 hallmarks of apoptosis. Concomitant inhibition of the caspase cascade protected neuroblastoma cells from cathepsin inhibitor-induced cytotoxicity. These data indicate that prolonged inhibition of the lysosomal proteolytic pathway is incompatible with cell survival, leading to apoptosis of neuroblastoma cells, and that the cathepsin-mediated and caspase-mediated proteolytic systems are connected and cooperate in the regulation of such an event. Since modern antitumor chemotherapy is aimed at restoring the normal rate of apoptosis in neoplastic tissues, the demonstration that endosomal-lysosomal cathepsins are involved in this process may constitute a basis for novel strategies that include cathepsin inhibitors in the therapeutic regimen. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11857353     DOI: 10.1002/ijc.10139

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  Endocytic mechanisms for targeted drug delivery.

Authors:  Lisa M Bareford; Peter W Swaan
Journal:  Adv Drug Deliv Rev       Date:  2007-06-28       Impact factor: 15.470

2.  Induction of cell death in neuroblastoma by inhibition of cathepsins B and L.

Authors:  Rita Colella; Guizhen Lu; Lisa Glazewski; Bruce Korant; Anjan Matlapudi; Matthew R England; Colin Craft; Christopher N Frantz; Robert W Mason
Journal:  Cancer Lett       Date:  2010-04-01       Impact factor: 8.679

3.  Enzymatically active cathepsin D sensitizes breast carcinoma cells to TRAIL.

Authors:  Blanka Jancekova; Eva Ondrouskova; Lucia Knopfova; Jan Smarda; Petr Benes
Journal:  Tumour Biol       Date:  2016-02-11

4.  Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer.

Authors:  S K Baird; J L Aerts; A Eddaoudi; M Lockley; N R Lemoine; I A McNeish
Journal:  Oncogene       Date:  2007-12-10       Impact factor: 9.867

5.  Post-translational regulation of cathepsin B, but not of other cysteine cathepsins, contributes to increased glioblastoma cell invasiveness in vitro.

Authors:  Boris Gole; María Beatriz Durán Alonso; Vincenc Dolenc; Tamara Lah
Journal:  Pathol Oncol Res       Date:  2009-05-13       Impact factor: 3.201

Review 6.  Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications.

Authors:  Gaetano Leto; Francesca M Tumminello; Marilena Crescimanno; Carla Flandina; Nicola Gebbia
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

7.  Inhibition of human natural killer cell activity by influenza virions and hemagglutinin.

Authors:  Huawei Mao; Wenwei Tu; Yinping Liu; Gang Qin; Jian Zheng; Ping-Lung Chan; Kwok-Tai Lam; J S Malik Peiris; Yu-Lung Lau
Journal:  J Virol       Date:  2010-02-17       Impact factor: 5.103

8.  Inhibition of cathepsin B by E-64 induces oxidative stress and apoptosis in filarial parasite.

Authors:  Mohit Wadhawan; Neetu Singh; Sushma Rathaur
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.